Please provide your email address to receive an email when new articles are posted on . The FDA granted breakthrough device designation to Quest Diagnostics’ Haystack MRD test for identifying patients ...
TORONTO -- Achieving minimal residual disease (MRD) negativity was associated with favorable safety outcomes and no effect on health-related quality of life among patients with newly diagnosed ...
The FDA granted breakthrough device designation to Quest Diagnostics’ Haystack MRD test for patients with stage 2 colorectal cancer after surgery. The U.S. Food and Drug Administration (FDA) has ...
The FDA's Breakthrough Devices Program accelerates access to promising medical devices for serious conditions, ensuring safety and effectiveness through a rigorous review process. Haystack MRD test ...
Panelists discuss how the PERSEUS trial’s subgroup analysis reinforced that sustained minimal residual disease negativity predicts better long-term outcomes and demonstrated the potential for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback